Table 2.
Comparison of the Sox9-Pten with Alb-Pten mice.
| Sox9-Cre | Albumin-Cre | |||
|---|---|---|---|---|
| 8.5–9.5 M | Controla (n = 7)b | Sox9-Pten (n = 7)b | Control (n = 16)b | Alb-Pten (n = 30)b |
| Fatty liverc | 0/6 | Periductal area | NO | Entire liver |
| VMCd | 0/6 | 4/7 (57.1%) | 0/16 (0%) | 30/30 (100%) |
| Tumorsd | 0/6 | 0/7 (0%)e | 0/16 (0%) | 14/30 (46.7%) |
| 11-13 M | Control (n = 13)2 | Sox9-Pten (n = 22)2 | Control (n = 126)2 | Alb-Pten (n = 48)2 |
|---|---|---|---|---|
| Fatty liverc | NO | Periductal area | NO | Entire liver |
| VMCd | 0/13 (0%) | 18/22 (81.8%) | 0/126 (0%) | 48/48 (100%) |
| Tumorsd | 0/13 (0%) | 14/22 (63.6%) | 0/126 (0%) | 48/48 (100%) |
VMC von Meyenburg complex.
aControl mice are: Pten loxP/loxP; Cre- mice with no treatment; Pten + / + ; Sox9-CreERT mice treated with either corn oil or tamoxifen; or PtenloxP/loxP; Sox9-CreERT mice treated with coil oil.
bThe number of mice in each cohort at different ages.
cThe location where lipids accumulate in the liver.
dOut of the total number of mice in each cohort (the number shown after slash), the number of mice developing these phenotypes is shown before slash. The percentage of mice developing these phenotypes in each cohort is shown accordingly in prentices.
eStatistically significantly different (P < 0.05) from that of Alb-Pten group using Fischer’s exact test.